U.S. Markets closed

Gilead Sciences and Galapagos Stock Are Rising on Upbeat Trial Data

Teresa Rivas

The two bioetchs said Phase 3 trial data for rheumatoid arthritis treatment filgotinib showed the drug met its primary endpoints and exhibited a safety profile consistent with previous research.